Fintel reports that on August 10, 2023, EF Hutton reiterated coverage of Lantern Pharma (NASDAQ:LTRN) with a Buy recommendation.
Analyst Price Forecast Suggests 278.59% Upside
As of August 2, 2023, the average one-year price target for Lantern Pharma is 17.68. The forecasts range from a low of 11.11 to a high of $27.30. The average price target represents an increase of 278.59% from its latest reported closing price of 4.67.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Lantern Pharma is 0MM. The projected annual non-GAAP EPS is -1.97.
What is the Fund Sentiment?
There are 42 funds or institutions reporting positions in Lantern Pharma. This is a decrease of 4 owner(s) or 8.70% in the last quarter. Average portfolio weight of all funds dedicated to LTRN is 0.03%, an increase of 114.09%. Total shares owned by institutions increased in the last three months by 5.97% to 1,200K shares. 
The put/call ratio of LTRN is 0.15, indicating a bullish outlook.
What are Other Shareholders Doing?
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 256K shares representing 2.36% ownership of the company. No change in the last quarter.
GWM Advisors holds 172K shares representing 1.59% ownership of the company. In it's prior filing, the firm reported owning 173K shares, representing a decrease of 0.42%. The firm increased its portfolio allocation in LTRN by 36,798.76% over the last quarter.
VEXMX - Vanguard Extended Market Index Fund Investor Shares holds 99K shares representing 0.91% ownership of the company. No change in the last quarter.
Carlson Capital L P holds 95K shares representing 0.88% ownership of the company. No change in the last quarter.
CM Management holds 75K shares representing 0.69% ownership of the company. In it's prior filing, the firm reported owning 60K shares, representing an increase of 20.00%. The firm increased its portfolio allocation in LTRN by 18.07% over the last quarter.
Lantern Pharma Background Information
(This description is provided by the company.)
Lantern Pharma (LTRN) is a clinical-stage biopharmaceutical company innovating the repurposing, revitalization and development of precision therapeutics in oncology. It leverages advances in machine learning, genomics, and artificial intelligence by using a proprietary A.I. platform to discover biomarker signatures that help identify patients more likely to respond to its pipeline of cancer therapeutics. Lantern's focus is to improve the outcome for patients by leveraging its technology to uncover, rescue and develop abandoned or failed drugs. Its current pipeline of three drugs, with two programs in clinical stages and two in preclinical, focuses on cancers that have unique and unmet clinical needs with a clearly defined patient population. It believes that the use of machine learning, genomics and computational methods can help accelerate the revitalization, refocusing and development of small molecule-based therapies. By targeting drugs to patients whose genomic profile identifies them as having the highest probability of benefiting from the drug, this approach represents the potential to deliver best-in-class outcomes. Its team seeks out experienced industry partners, world-class scientific advisors, and innovative clinical-regulatory approaches to assist in delivering cancer therapies to patients as quickly and efficiently as possible.
Additional reading:
- Lantern Pharma Reports Second Quarter 2023 Financial Results and Operational Highlights
- Fourth Amendment, dated January 1, 2023, to Employment Agreement with Kishor Bhatia dated May 18, 2020
- Lantern Pharma Reports First Quarter 2023 Financial Results and Operational Highlights
- Presentation relating to May 9, 2023 conference call and live webinar to discuss financial and operating results for quarter ended March 31, 2023.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
